Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03095248 · ClinicalTrials.gov registry record · Phase 2
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
A Phase 2 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03095248 is a Phase 2 study that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 10 participants.
The verdict
NCT03095248, a Phase 2 study, was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor. The researchers are asking patients with NF2 related tumors to be in the study, because their hearing has decreased and/or their NF2 related tumor has started to grow. The goals of this study are: * Determine if selumetinib will stop NF2 related tumors from growing * Measure the changes in hearing after receiving selumetinib for 6 months. * Determine if selumetinib improves how participants feel (physically and emotionally) and how participants can perform daily activities. * Examine tumor tissue, if available, in a laboratory to see if NF2 related tumors have targets of selumetinib.
Interventions
- DRUG Selumetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2024-05-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03095248
The ClinicalTrials.gov registry entry for NCT03095248 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selumetinib is the first listed.
NCT03095248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03095248 about?
NCT03095248 is a clinical study titled "Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors". In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor. The researchers are asking patients with NF2 related tumors to be in the study, because their hearing ha...
What is the current status of trial NCT03095248?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-05-08. Estimated completion is 2024-05-21.
What interventions are being tested in trial NCT03095248?
The interventions under investigation include: Selumetinib (DRUG).
Who is sponsoring clinical trial NCT03095248?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.